Cover Image
市場調查報告書

中風:開發平台分析

Stroke - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229744
出版日期 內容資訊 英文 461 Pages
訂單完成後即時交付
價格
Back to Top
中風:開發平台分析 Stroke - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 461 Pages
簡介

所謂中風是因為缺氧導致腦細胞死亡的症狀。症狀是會突然發生,並在短時間(通常數分到數小時)結束。最初患者會感到身體不適,臉色蒼白、精神非常差。還有可能產生突然性頭痛,或是突然臉部或手腳,尤其是身體一邊麻痺。口齒不清,或無法理解別人說話的內容、視力下降、走路難以保持平衡等症狀。甚至也會因癲癇發作而產生窒息。

本報告提供全球各國治療中風所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

中風概要

治療藥的開發

  • 中風開發中產品:概要
  • 中風開發中產品:比較分析

各企業開發中的中風治療藥

大學/研究機關研究中的中風治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

中風治療藥:開發中的產品一覽(各企業)

中風治療藥:研究中的產品一覽(各大學/研究機關)

中風治療藥的開發企業

  • AB Science SA
  • Acorda Therapeutics, Inc.
  • Acticor Biotech
  • ActiveSite Pharmaceuticals, Inc.
  • Addex Therapeutics Ltd
  • advanceCor GmbH
  • Affibody AB
  • Amarantus Bioscience Holdings, Inc.
  • Anavex Life Sciences Corp.
  • Angion Biomedica Corp.
  • Antoxis Limited
  • Aralez Pharmaceuticals Inc.
  • ArmaGen Inc.
  • Asterias Biotherapeutics, Inc.
  • AstraZeneca Plc
  • Athersys, Inc.
  • Bayer AG
  • Bioasis Technologies Inc.
  • Biogen, Inc.
  • BioTime, Inc.
  • Cardax Pharmaceuticals, Inc.
  • Cellular Biomedicine Group, Inc.
  • CHA Bio & Diostech Co., Ltd.其他

中風:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

中風治療藥:開發中產品的最新趨勢

中風治療藥:暫停開發的產品

中風治療藥:中止開發的產品

中風相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9299IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Stroke - Pipeline Review, H1 2017, provides an overview of the Stroke (Cardiovascular) pipeline landscape.

Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Stroke - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 22, 15, 1, 87 and 11 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 31 and 3 molecules, respectively.

Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Stroke - Overview
  • Stroke - Therapeutics Development
  • Stroke - Therapeutics Assessment
  • Stroke - Companies Involved in Therapeutics Development
  • Stroke - Drug Profiles
  • Stroke - Dormant Projects
  • Stroke - Discontinued Products
  • Stroke - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Stroke, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Stroke - Pipeline by AB Science SA, H1 2017
  • Stroke - Pipeline by Acticor Biotech SAS, H1 2017
  • Stroke - Pipeline by ActiveSite Pharmaceuticals Inc, H1 2017
  • Stroke - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Stroke - Pipeline by Affibody AB, H1 2017
  • Stroke - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Stroke - Pipeline by Angion Biomedica Corp, H1 2017
  • Stroke - Pipeline by Antoxis Ltd, H1 2017
  • Stroke - Pipeline by ArmaGen Inc, H1 2017
  • Stroke - Pipeline by Artielle ImmunoTherapeutics Inc, H1 2017
  • Stroke - Pipeline by Asterias Biotherapeutics Inc, H1 2017
  • Stroke - Pipeline by Athersys Inc, H1 2017
  • Stroke - Pipeline by Bayer AG, H1 2017
  • Stroke - Pipeline by Bioasis Technologies Inc, H1 2017
  • Stroke - Pipeline by Biogen Inc, H1 2017
  • Stroke - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Stroke - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Stroke - Pipeline by Cardax Inc, H1 2017
  • Stroke - Pipeline by Cellular Biomedicine Group Inc, H1 2017
  • Stroke - Pipeline by CHA Bio & Diostech Co Ltd, H1 2017
  • Stroke - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017
  • Stroke - Pipeline by CSPC Pharmaceutical Group Limited, H1 2017
  • Stroke - Pipeline by D-Pharm Ltd, H1 2017
  • Stroke - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Stroke - Pipeline by DiaMedica Therapeutics Inc, H1 2017
  • Stroke - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
  • Stroke - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Stroke - Pipeline by Fina Biotech SL, H1 2017
  • Stroke - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017
  • Stroke - Pipeline by Glialogix Inc, H1 2017
  • Stroke - Pipeline by Glucox Biotech AB, H1 2017
  • Stroke - Pipeline by Green Cross Corp, H1 2017
  • Stroke - Pipeline by Huons Co Ltd, H1 2017
  • Stroke - Pipeline by Immunwork Inc, H1 2017
  • Stroke - Pipeline by International Stem Cell Corp, H1 2017
  • Stroke - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
  • Stroke - Pipeline by JN-International Medical Corp, H1 2017
  • Stroke - Pipeline by JT Pharmaceuticals Inc, H1 2017
  • Stroke - Pipeline by Les Laboratoires Servier SAS, H1 2017
  • Stroke - Pipeline by Living Cell Technologies Ltd, H1 2017
  • Stroke - Pipeline by Lumosa Therapeutics Co Ltd, H1 2017
  • Stroke - Pipeline by M et P Pharma AG, H1 2017
  • Stroke - Pipeline by Magnus Life Ltd, H1 2017
  • Stroke - Pipeline by Mapreg SAS, H1 2017
  • Stroke - Pipeline by Medestea Research & Production SpA, H1 2017
  • Stroke - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017
  • Stroke - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
  • Stroke - Pipeline by Neuralstem Inc, H1 2017
  • Stroke - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017
  • Stroke - Pipeline by Neurofx Inc, H1 2017
  • Stroke - Pipeline by Neuronax SAS, H1 2017
  • Stroke - Pipeline by NeuroSearch A/S, H1 2017
  • Stroke - Pipeline by NeuroVive Pharmaceutical AB, H1 2017
  • Stroke - Pipeline by New World Laboratories Inc, H1 2017
  • Stroke - Pipeline by NoNO Inc, H1 2017
  • Stroke - Pipeline by Novartis AG, H1 2017
  • Stroke - Pipeline by NuvOx Pharma LLC, H1 2017
  • Stroke - Pipeline by Omeros Corp, H1 2017
  • Stroke - Pipeline by Omniox Inc, H1 2017
  • Stroke - Pipeline by Panacea Pharmaceuticals Inc, H1 2017
  • Stroke - Pipeline by Pharmaxis Ltd, H1 2017
  • Stroke - Pipeline by Pharmicell Co Ltd, H1 2017
  • Stroke - Pipeline by Phoenix Biotechnology Inc, H1 2017
  • Stroke - Pipeline by PhytoHealth Corp, H1 2017
  • Stroke - Pipeline by Pluristem Therapeutics Inc, H1 2017
  • Stroke - Pipeline by QR Pharma Inc, H1 2017
  • Stroke - Pipeline by ReCyte Therapeutics Inc, H1 2017
  • Stroke - Pipeline by Remedy Pharmaceuticals Inc, H1 2017
  • Stroke - Pipeline by ReNeuron Group Plc, H1 2017
  • Stroke - Pipeline by Rubicon Biotechnology Inc, H1 2017
  • Stroke - Pipeline by SanBio Inc, H1 2017
  • Stroke - Pipeline by Saneron CCEL Therapeutics Inc, H1 2017
  • Stroke - Pipeline by Savara Inc, H1 2017
  • Stroke - Pipeline by Shin Poong PharmCo Ltd, H1 2017
  • Stroke - Pipeline by Simcere Pharmaceutical Group, H1 2017
  • Stroke - Pipeline by Stemedica Cell Technologies Inc, H1 2017
  • Stroke - Pipeline by SynZyme Technologies LLC, H1 2017
  • Stroke - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
  • Stroke - Pipeline by TikoMed AB, H1 2017
  • Stroke - Pipeline by Verseon Corp, H1 2017
  • Stroke - Pipeline by Vicore Pharma AB, H1 2017
  • Stroke - Pipeline by Virogenomics BioDevelopment Inc, H1 2017
  • Stroke - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017
  • Stroke - Pipeline by Zocere Inc, H1 2017
  • Stroke - Dormant Projects, H1 2017
  • Stroke - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Stroke - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Stroke - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Stroke - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Stroke - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Stroke - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Stroke - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Stroke - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Stroke - Discontinued Products, H1 2017
  • Stroke - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Stroke - Discontinued Products, H1 2017 (Contd..2), H1 2017

List of Figures

  • Number of Products under Development for Stroke, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top